Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals Inc (NY: AMRX )

N/A UNCHANGED
Last Price Updated: 7:00 PM EST, Dec 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 Next >
Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at Upcoming Investor Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Assessing Amneal Pharmaceuticals: Insights From 4 Financial Analysts
Via Benzinga
Generic Drugmaker Amneal Announces Over $270M In US Opioid Lawsuit Settlement
Amneal Pharmaceuticals settles $270 million opioid crisis agreement, offering cash and naloxone spray. Boosted by strong Q1 earnings, the company reaffirms fiscal guidance. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Amneal Pharmaceuticals: Q4 Earnings Insights
Via Benzinga
Earnings Outlook For Amneal Pharmaceuticals
Via Benzinga
AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
AMRX stock results show that Amneal Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Amneal Reports First Quarter 2024 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report First Quarter 2024 Results on May 3, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Why Is Generic Drug-Focused Amneal Pharmaceuticals Stock Trading Lower Friday?
Amneal Pharmaceuticals reveals Q4 2023 results with $616.98 million revenue, up 1% YoY. Despite an 8% drop in adjusted EBITDA, the company beats EPS expectations. Co-CEOs anticipate growth in 2024,... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking on Friday as investors prepare for the last day of trading this week with all of the latest news! 
Via InvestorPlace
Earnings Scheduled For March 1, 2024
Companies Reporting Before The Bell • McEwen Mining (NYSE:MUX) is estimated to report quarterly loss at $0.28 per share on revenue of $71.72 million. 
Via Benzinga
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
From Amneal Pharmaceuticals, Inc.
Via Business Wire
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why 
Via MarketBeat
Topics Lawsuit
Exposures Financial Legal
Amneal to Participate at Upcoming Investor Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces Move to Nasdaq
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports Third Quarter 2023 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS